Law360, New York (March 26, 2010, 5:12 PM ET) -- A federal jury has found that Pfizer Inc. improperly marketed its epilepsy drug Neurontin in violation of racketeering and competition laws, awarding plaintiff Kaiser Foundation Health Plan Inc. over $142 million.
The jury handed down its verdict late Thursday in the U.S. District Court for the District of Massachusetts after a monthlong trial, determining that Pfizer fraudulently marketed Neurontin for numerous unapproved or off-label uses, including bipolar disorder, neuropathic pain and migraines, and misrepresented the drug's capacity to treat those conditions.
The actions violated both federal...
Jury Hands $142M Win To Kaiser In Neurontin Battle
To view the full article, take a free trial now.
